New 20 year patents threaten to end AIDS drugs for developing countries
BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7478.1308-c (Published 02 December 2004) Cite this as: BMJ 2004;329:1308- Owen Dyer
- London
Efforts to bring antiretroviral treatment to AIDS patients in developing countries are threatened by the looming implementation of new World Trade Organisation's patent rules, the charity Médecins Sans Frontières warned this week.
The organisation's TRIPS (trade related aspects of intellectual property rights) agreement comes into force for most signatories on 1 January 2005. It requires the organisation's members to grant 20 year patents to new pharmaceutical products. Only the least developed countries can postpone implementation until 2016.
Médecins Sans Frontières' international president, Dr Rowan Gillies, told the BMJ …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.